Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

108.25 -0.13 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 490,039
Open 108.67
Bid (Size) 107.81 (1)
Ask (Size) 108.62 (1)
Prev. Close 108.38
Today's Range 108.03 - 109.52
52wk Range 73.13 - 129.29
Shares Outstanding 94,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
7 A-Rated Stocks to Buy for Less Than $25
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market. 
Via InvestorPlace

Performance

YTD
-9.85%
-9.85%
1 Month
-9.94%
-9.94%
3 Month
-5.97%
-5.97%
6 Month
+17.62%
+17.62%
1 Year
+41.08%
+41.08%

More News

Read More
Why Voyager Therapeutics Stock Is Sinking This Week
Via The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Via Investor's Business Daily
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
Via InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally
Via Investor's Business Daily
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Via Benzinga
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Via MarketBeat
Looking Into Neurocrine Biosciences's Return On Capital Employed
Via Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
Via Investor's Business Daily
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
Via Investor's Business Daily
Neurocrine Biosciences: Q3 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Earnings Scheduled For November 1, 2022
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
4 Analysts Have This to Say About Neurocrine Biosciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
Via Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.